Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is an ingredient of chili peppers with inhibitory effects against cancer cells of different origin. We examined the activity of capsaicin on breast cancer cells in vitro and in vivo. The drug potently inhibited growth of ER-positive (MCF-7, T47D, BT-474) and ER-negative (SKBR-3, MDA-MB231) breast cancer cell lines, which was associated with G 0 /G 1 cell-cycle arrest, increased levels of apoptosis and reduced protein expression of human epidermal growth factor receptor (EGFR), HER-2, activated extracellular-regulated kinase (ERK) and cyclin D1. In contrast, cell-cycle regulator p27
Introduction
Breast cancer is the second leading cause of cancer death in women, exceeded only by lung cancer (Morris and Mitchell, 2008) . Although significant advances have been made in the treatment of this cancer, only less than half of the patients treated for localized breast cancer benefit from adjuvant chemotherapy; and most patients with metastatic cancer eventually develop disease that is resistant to therapy (Gonzalez-Angulo et al., 2007) . Moreover, systemic treatment of breast cancer causes acute and chronic toxicities including congestive heart failure, neuropathy, sterility and osteoporosis (Rock and DeMichele, 2003) .
Numerous naturally occurring substances have potential value as antioxidants, cancer-preventive agents or even as cancer therapeutic drugs. Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide), a vanilloid receptor agonist, is the major pungent principle found in chili peppers of the plant genus Capsicum (Monsereenusorn et al., 1982) . This alkaloid compound has an in vitro antiproliferative effect on prostate (Mori et al., 2006; Sa´nchez et al., 2006) , colon (Kim et al., 2004) , gastric (Lo et al., 2005) , hepatic (Jung et al., 2001) and leukemic cancer cells (Ito et al., 2004) while leaving normal cells unharmed (Ito et al., 2004; Athanasiou et al., 2007) . One study so far showed growth-inhibitory effects of capsaicin on single MCF-7 breast cancer cell line but gave no detailed insights into the potential underlying molecular mechanisms (Tuoya et al., 2006) .
However, capsaicin-induced growth inhibition and apoptosis is independent of its stimulatory effects on the vanilloid receptors, because co-treatment with competitive vanilloid receptor inhibitors like capsazepin did not affect the antiproliferative activity of the drug (Kim et al., 2004; Athanasiou et al., 2007) . The molecular mechanisms involved in the anticancer actions of capsaicin are complex, and the targets and the molecular mechanisms by which it initiates death of cancer cells are incompletely understood. We have previously shown that capsaicin has multiple molecular effects on prostate cancer cells, including suppression of transcription of prostate-specific antigen, as well as inhibition of proteosome function and NF-kB activation (Mori et al., 2006) . Other studies have shown that capsaicin was able to decrease the production of reactive oxygen species by inhibition of the NADHdependent plasma membrane electron transport system with a subsequent disruption of mitochondria transmembrane potential (Morre et al., 1995; Hail and Lotan, 2002) .
Overexpression of the human epidermal growth factor receptor (EGFR/HER-1/ERBb1) and epidermal growth factor-2 (HER-2/HER2/neu/ERBb2) has been associated with a more aggressive course of disease in human breast carcinomas (Mendelsohn and Baselga, 2000; Me´nard et al., 2003) . Therefore, these two receptor tyrosine kinases represent one of the most interesting targets for breast-cancer-specific therapy. The goal of this study was to determine the range of antiproliferative activities of capsaicin against breast cancer cells both in vitro and in vivo, and to investigate how the drug mediated this activity. We particularly focused on the EGFR/HER-2 pathway including downstream progrowth signaling and cell-cycle modulating proteins.
Results

Effect of capsaicin on proliferation, cell cycle and apoptosis of breast cancer cells
The ability of capsaicin to inhibit the proliferation of a panel of ER-positive and -negative breast cancer cell lines was tested using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Capsaicin inhibited the proliferation of each of the breast cancer cell lines (MCF-7, SKBR-3, MDA-MB231, T47D and BT-474) in a dose-dependent manner, with an ED 50 between 5 Â 10 À5 and 2 Â 10 À4 M (Figure 1a ). The ERnegative MDA-MB231 cells showed to be less sensitive to the compound, whereas ER-negative SKBR-3 cells were the most sensitive compared to the other investigated breast cancer cell lines. Noteworthy, the proliferation of the untransformed human mammary epithelial cell line MCF-10A was only slightly affected by capsaicin exposure.
The cell-cycle distribution was studied by flow cytometry in BT-474, SKBR-3 and MDA-MB231 cells. In all cell lines, treatment with capsaicin caused a timeand dose-dependent growth arrest in the G 0 /G 1 phase of the cell cycle and a decrease of cells in the S phase ( Figure 1b) . For example, after 72 h exposure to 2 Â 10 À4 M capsaicin, BT-474, SKBR-3 and MDA-MB231 cells showed a markedly increase by 67% (P ¼ 0.001), 46% (P ¼ 0.008) and 55% (P ¼ 0.005), respectively, in the G 0 /G 1 phase, whereas the percentages of cells in the S phase were reduced in the same pattern.
The ability of capsaicin to induce apoptosis was measured by Annexin V-FITC (fluorescein isothiocyanate) and propidium iodide (PI) labeling of BT-474, SKBR-3, MDA-MB231 and MCF-7 cells after treatment with 2 Â 10 À4 M capsaicin for 72 h. The proportion of apoptotic cells was significantly increased after 24 h exposure to capsaicin in all four breast cancer cell lines (Po0.05), and more than 80% of the cells were positive for Annexin V-FITC and PI after 72 h (Po0.001; Figure 2 ). In comparison, cells treated with diluent control (dimethyl sulfoxide, DMSO) were less than 15% positive after 72 h.
Modulation of the EGFR/HER-2 pathway by capsaicin EGFR and HER-2 are important in breast cancer progression, and can exert their effects by signaling through intracellular kinases, which can lead to progressive tumor growth and invasion (Mendelsohn and Baselga, 2003; Scaltriti and Baselga, 2006) . The ability of capsaicin to inhibit the levels of EGFR pathwayrelated proteins was examined in ER-positive BT-474 as well as ER-negative SKBR-3 and MDA-MB231 cell lines. Capsaicin (2 Â 10 À4 M) dramatically reduced the protein expression of both EGFR and HER-2 in BT-474 and SKBR-3 cells (Figure 3a) . In comparison, the drug decreased the EGFR and HER-2 levels in MDA-MB231 cells only to a lesser extend after 24 h of drug exposure. The modulating activity of capsaicin on the expression of EGFR and HER-2 was not found on mRNA levels ( Figure 3b ).
Moreover, cell-cycle regulator cyclin D1 protein levels decreased whereas cyclin-dependent kinase inhibitor p27 KIP1 increased in capsaicin-treated BT-474, SKBR-3 and MDA-MB231 cell lines (Figure 3a) . This was associated with caspase-3, -7, -9 activation and subsequent appearance of apoptosis-specific PARP (poly-ADP ribose polymerase) cleavage products. The expression levels of cyclin A, cyclin B1, cdk-2 and p21 WAF1 did not change in the capsaicin-treated cell lines (data not shown).
The activation of extracellular-regulated kinase (ERK), one major downstream signaling protein of the EGFR/HER-2 signaling pathway, was clearly inhibited by capsaicin in BT-474 and SKBR-3 cell lines after serum-starved cells were stimulated with EGF (representative data shown for BT-474 in Figure 4 ). We found that the levels of phosphorylated ERK were decreased by capsaicin even in MDA-MB231 cells, which are known to have constitutively activated ERK. In contrast, capsaicin had no influence on the expression levels of activated AKT or signal transducer and activator of transcription 3 (STAT3) in any of the three cell lines (Figure 4 ; data for SKBR-3 not shown). Effect of capsaicin on EGFR-dependent migration of breast cancer cells Overexpression of EGFR/HER-2 and downstream signaling protein ERK can also be important in breast cancer migration (Mendelsohn and Baselga, 2000; Krueger et al., 2001) . We tested the ability of capsaicin to inhibit EGF-dependent migration of breast cancer cells in a Boyden chamber assay. Control cells of the breast cancer cell lines BT-474, SKBR-3 and MDA-MB231 placed in the upper chamber were able to migrate toward EGF in the bottom chamber (Po0.01).
In contrast, the cell migration was inhibited in all cell lines when the assay was performed in the presence of capsaicin (Figure 5a ).
Effect of capsaicin on orthotopic growth of breast cancer in vivo The aggressive, EGFR-positive, p53 mutant MDA-MB231 breast cancer cells were grown orthotopically in the breast tissue of female BNX nu/nu mice; and capsaicin (5 mg/kg per day) or vehicle was administered by oral gavage three times per week. Mice (six animals per group) were killed after 4 weeks and 12 tumors per group were dissected and weighed. The mean weight of tumors in capsaicin-treated mice was significantly less than the control group (502±102 vs 1642±614 mg, respectively; P ¼ 0.01; Figure 5b ). The mice that received capsaicin acted and appeared completely normal with no signs of discomfort or impaired movement. In addition, the body weight of capsaicin-treated mice showed no significant changes compared to the vehicletreated mice (data not shown). Concordantly with our in vitro results, tumors of mice treated with capsaicin had lower levels of activated ERK, as well as HER-2 and cyclin D1, whereas caspase-3, -7, -9 activity along with PARP cleavage products was increased compared to the tumors from the control mice ( Figure 5c ).
Effect of capsaicin on formation of DMBA-induced mammary lesions
To examine the efficacy of capsaicin in preventing the formation of alveolar and ductal lesions, in each case 30 mammary glands from BALB/c mice were incubated with growth hormones either with capsaicin (10 À8 -10 À5 M) or diluent control and exposed either with or without 7,12-dimethyl-benz[a]anthracene (DMBA) on day 3 of culture for 24 h. The glands were cultured for an additional 14 days after ± DMBA treatment. Figure 6a shows representative photographs how capsaicin prevented mammary alveolar lesions under DMBA treatment, whereas Figure 6b shows representative ductal lesions induced by DMBA and their prevention by capsaicin. We could show by histopathology investigations that under treatment of capsaicin the precancerous alveolar and ductal lesions were predominantly inhibited whereas healthy tissue of mammary fat pads and mammary ducts persisted. Glands treated with capsaicin showed no histological evidence of toxicity at the concentrations used in the organ culture assays. The percent inhibition of formation of lesions was calculated by the comparison of the incidence of DMBA-induced lesions between the diluent control-treated and the respective capsaicin-treated group. Capsaicin significantly inhibited glands exhibiting lesions in a dosedependent manner (Figure 6c ). The drug was able to suppress the formation of alveolar and ductal lesions by more than 80% (Po0.001) and 65% (P ¼ 0.006), respectively, at concentrations of o1 Â 10
Discussion
The goal of this study was to determine whether the vanilloid capsaicin exerted antiproliferative activity against breast cancer cells in vitro as well as vivo. in vitro, treatment with capsaicin markedly inhibited proliferation of both ER-positive and -negative breast cancer cells, whereas the compound showed only a minor effect on growth of untransformed MCF-10A breast cells. The growth-inhibitory effect of capsaicin on the breast cancer cells was clearly associated with cell-cycle arrest and apoptosis.
We further studied the EGFR family and its downstream targets to analyse the molecular background of these findings. The EGFR/HER-2 signaling pathway actively contributes to a number of processes important to cancer, including cell proliferation, angiogenesis and metastatic spread in a number of human solid tumors including breast. Amplification of the proto-oncogene HER-2 is detected in 25-30% of human breast cancers, which is predictive of poor clinical outcome (Mendelsohn and Baselga, 2000; Me´nard et al., 2003) . Aberrant signaling through HER-2 is believed to have a direct role in malignant transformation and/or progression by being able to format homodimers, and maintaining constitutive ligand-independent stimulation of signaling pathways (Mendelsohn and Baselga, 2000; Me´nard et al., 2003) . EGFR is reported to be expressed in 14-91% of breast cancer patients, and it has also been associated with poor prognosis (Mendelsohn and Baselga, 2000; Magkou et al., 2008) . In this study, capsaicin was able to decrease the protein levels of both HER-2 and EGFR in breast cancer cell lines. In HER-2 overexpressing BT-474 and SKBR-3 cell lines, which only have low to moderate levels of EGFR, capsaicin was able to clearly reduce expression levels of both types of receptors. In contrast, the drug showed less activity in the MDA-MB231 cell line, which is known to overexpress HER-2 as well as EGFR. Under the same culture conditions, capsaicin did not alter the mRNA levels of EGFR and HER-2 in all three breast cancer cell lines, suggesting that capsaicin decreases the two receptors by affecting their protein stability. It has also been shown that aberrant HER-2 activity is important in tumor initiation as well as in the emergence of aggressive cellular behavior associated with progressive disease (Korkaya et al., 2008) . Experimental support for the role of HER-2 in breast cancer initiation also comes from transgenic experiments in which wildtype or activated HER-2 expressed in mouse mammary epithelium leads to a high frequency of mammary carcinomas (Carraway and Sweeney, 2006) . Interestingly, we showed that capsaicin markedly inhibited preneoplastic mammary gland lesions in a murine organ culture model.
Hetero-and homodimerization of EGFR and/or HER-2 can lead to the downstream activation of the RAS/RAF/ERK, phosphatidylinositol 3-kinase (PI3K)/ AKT as well as the STAT3 pathways, which are known to modulate cancer growth and progression (Mendelsohn and Baselga, 2000; Me´nard et al., 2003; Korkaya et al., 2008) . Moreover, elevated HER-2 activity can reduce the general growth factor dependence of HER-2 amplified breast cancer cells though prolonged stimulation of the RAS/RAF/ERK pathway (Eckert et al., 2004; Montgomery et al., 2005) . In this study, exposure to capsaicin clearly inhibited the activation of ERK in both BT-474 and SKBR-3 cells. Again, the drug was more effective in these two cell lines compared with the MDA-MB231 cell line known to have constitutively activated ERK (Fukazawa et al., 2002) . All in all, it seemed that the downregulation of the EGFR/HER-2 pathway including ERK downstream signaling was, in part, a specific effect of capsaicin because the drug showed no concomitant inhibitory activity toward AKT and STAT3 signaling. We suggest that the activation of these two EGFR/HER-2 downstream signaling molecules was sustained by other receptor and nonreceptor tyrosine kinases, such as the IL-6/gp130 receptor family, PDGFR, src kinase or JAKs.
Regarding the sensitivity of capsaicin to inhibit growth and induce apoptosis in breast cancer, we found relatively similar effects in almost all investigated cell lines irrespective of their ER status. The drug had almost similar effects on the ER-negative cell line SKBR-3 in comparison to the ER-positive cell line BT-474. An exemption was the EGFR/HER-2-overexpressing cell line MDA-MB231. We therefore suggest that the sensitivity of the breast cancer cells to capsaicin is rather more dependent on their expression levels of EGFR/HER-2 than their ER status. An overview of how capsaicin may achieve its efficacy against breast cancer cells is given in Figure 7 .
Studies using ERK signaling pathway inhibitors have established one further important role for the ERK signaling pathway in regulating cell motility (Mendelsohn and Baselga, 2000; Krueger et al., 2001) . We could show that capsaicin treatment clearly inhibits migration of breast cancer cells in the Boyden chamber assay, which we attribute to the inhibition of ERK activation by the compound. Capsaicin-treated breast cancer cells showed also decreased levels of cyclin D1, increased activity of p27 KIP1 and caspase-3, -7, -9 as well as appearance of the PARP cleavage product, which was in association with a G 0 /G 1 cell-cycle arrest and increased level of apoptosis. Interestingly, it has been shown that increased ERK activity in breast cancer contributes to the downregulation of p27 KIP1 and also to the upregulation of cyclin D1 expression by increasing its promoter activity (Lavoie et al., 1996; Kawada et al., 1997; Sivaraman et al., 1997) . These mechanisms can reduce dependence on normal physiological growth stimuli, and provide a growth advantage to tumor cells, a potential mechanism of resistance.
in vivo, capsaicin exhibited anticancer effects against EGFR-positive, -negative MDA-MB231 breast carcinoma cells grown orthotopically in the breast tissue of female immunodeficient mice. We were able to confirm our in vitro results by detecting lower protein levels of activated ERK, HER-2 and cyclin D1, and increased levels of caspase-3, -7 and -9 as well as PARP cleavage Capsaicin Figure 4 Capsaicin modulates epidermal growth factor (EGF)-induced extracellular-regulated kinase (ERK) phosphorylation in breast cancer cells. Cells were incubated either with or without capsaicin (10 À5 M) overnight in the absence of serum. Then, EGF (100 ng/ml) was added to control and capsaicin-treated wells for the indicated times. Western blots were sequentially probed with antibodies against epidermal growth factor receptor (EGFR), phospho-ERK, ERK, phospho-AKT, AKT, phospho-STAT3, STAT3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
products in tumors of drug-treated mice compared with the control mice. At present, human HER-2-positive breast cancers are treated with targeted therapies such as trastuzumab (Herceptin), an anti-HER-2 antibody, and lapatinib (GW572016/Tykerb), a selective small molecule inhibitor of HER-2 which was recently approved for HER-2-positive breast cancers that progressed on trastuzumab-based therapy. Unfortunately, the efficacy of trastuzumab or lapatinib as a monotherapy or in combination with chemotherapy, however, is limited in most advanced stages of HER-2-positive breast cancers by the development of therapeutic resistance that typically occurs within 12 months of starting therapy (Chen et al., 2008) . The development of hormone resistance is also an important factor in breast cancer progression against endocrine therapy. Increased EGFR or HER-2 activity may lead to resistance against tamoxifen, a selective estrogen receptor modulator (Schafer et al., 2002) . Capsaicin, which we showed to modulate the EGFR/HER-2 pathway including activated ERK, cyclin D1 and p27
KIP1
, may therefore help to overcome resistance in the early or advanced stages of human breast cancer.
However, as the pharmacokinetics of capsaicin in humans has not yet been investigated, predicting the amount of chili peppers that would need to be consumed to achieve the effective concentration of capsaicin observed in our animal model is unclear. The daily intake of capsaicin in India, Thailand, Korea and Mexico has been estimated to be 25-200 mg per person per day assuming the content of capsaicin in capsicum species is about 1% (Taik-koo, 1999; Council of Europe, 2001) . These data suggest that an effective level of capsaicin may be clinically achievable in patients. In a recent study, 50 mg/kg per day of capsaicin was injected into mice for a xenograft model with no apparent side effects (Ito et al., 2004) ; and except for a significant reduction in crown-rump length in day 18 rats injected subcutaneously with capsaicin 50 mg/kg capsaicin on gestation days 14, 16, 18 or 20, no reproductive or developmental toxicity was noted (Johnson, 2007) . In our study, the capsaicin-treated mice tolerated the therapy of 5 mg/kg capsaicin orally on 3 days per week with no unwanted side effects; and in vitro cultured mammary glands treated with up to 10 À5 M capsaicin displayed no histological evidence of toxicity.
In conclusion, we showed for the first time that capsaicin has profound in vitro and in vivo antiproliferative effects against breast cancer cells. The ability of capsaicin to suppress EGFR, HER-2 and activated ERK provides a sound basis for further exploring the use of capsaicin either alone or in combination with other agents to prevent recurrence or to reduce growth of breast cancer in patients.
Materials and methods
Cells and compounds
Five breast cancer cell lines (MCF-7, T47D, BT-474, SKBR-3 and MDA-MB231) and the untransformed human mammary epithelial cell line MCF-10A were obtained from the American Type Culture Collection (Rockville, MD, USA). Cancer cells were cultured in RPMI 1640 (Life Technologies, Rockville, MD, USA), with the exception of MCF-7 cells (Dulbecco's modified Eagle's medium, DMEM) and SKBR-3 cells (McCoy's). All cultured cancer cells were supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS; Gemini BioProducts, Carlsbad, CA, USA). The MCF-10A cell line was cultured in a 1:1 mixture of Ham's F12 medium and DMEM containing cholera enterotoxin (100 ng/ml), EGF (20 ng/ml) and 5% horse serum. All cultures were incubated at 37 1C and 5% CO 2 in a humidified incubator. Capsaicin (M-2028; Sigma Chemical Co, St Louis, MO, USA) was dissolved in absolute ethanol to make 10 À1 M stock solutions, and stored at À20 1C. Human EGF (Peprotech, Rocky Hill, NJ, USA) was dissolved in tissue culture media and also stored at À20 1C.
Measurement of cellular proliferation, cell cycle and apoptosis
All five breast cancer cell lines and the human mammary epithelial cell line MCF-10A were placed into 96-well plates at 5 Â 10 3 cells in 100 ml per well and treated with either DMSO (dilutent control) or different concentrations of capsaicin (10
À6
-10 À3 M). The cells were incubated at 37 1C for 96 h, a time point selected as it was previously determined to be optimal for MTT proliferation assays (Kumagai et al., 2003) . MTT (10 ml; Sigma Chemical Co), which was dissolved in phosphate-buffered saline (PBS), was added at 5 mg/ml to each well. After 4 h of further incubation, 100 ml of solubilization solution (20% sodium dodecyl sulfate, SDS) was added, and the mixture was incubated again for 16 h. The absorbance of the product was measured with an enzyme-linked immunosorbent assay reader at 540 nm.
The ER-positive BT-474 as well as ER-negative SKBR-3 and MDA-MB231 breast cancer cell lines were analysed for Figure 7 Overview of EGFR/HER-2 dimerization and extracellular-regulated kinase (ERK) signaling and how capsaicin may modulate this pathway. The cell membrane receptor tyrosine kinases epidermal growth factor receptor (EGFR) and HER-2, which are often overexpressed in breast cancer, are well-known mediators of cell proliferation, migration, differentiation and apoptosis. Binding of specific natural ligands like EGF or other growth factors to the extracellular domain of EGFR results in hetero-or homodimerization of the receptor. This leads to phosphorylation of intracellular tyrosine kinases and downstream activation of multiple pathways, including RAS/RAF/ERK. HER-2 is also able to dimerize with itself, and while there is no known ligand for HER-2, this receptor has a pivotal role in HER-2-mediated signaling as the preferred partner for dimerization with EGFR. The aberrant signaling through HER-2 in breast cancer is believed to have a direct role in malignant transformation and/or progression by maintaining constitutive active with enforced signaling through intracellular kinases such as ERK. In this study, capsaicin was able to downregulate the levels of EGFR/HER-2 in breast cancer cell lines, which subsequently affected the activation of ERK and other downstream targets like p27 KIP1 , cyclin D1 and PARP (poly-ADP ribose polymerase). This was associated with G 0 /G 1 cell-cycle arrest, increased levels of apoptosis as well as inhibition of pre-neoplastic lesions and in vivo breast tumors grown orthotopically in mice.
cell-cycle alterations after treating them for 24, 48 and 72 h with either DMSO or two different concentrations of capsaicin (1 Â 10 À5 and 2 Â 10 À4 M). After being trypsinized and washed twice with ice-cold PBS, we fixed cells (10 5 ) in 70% methanol overnight. The samples were then treated by DNase-free RNAase A (100 mg/ml) and exposed to PI (500 nM) for 30 min with subsequent analysis by flow cytometry (FACScan; Becton Dickinson, San Jose, CA, USA).
Cellular apoptosis was measured using the Annexin V assay (Annexin V-FITC Apoptosis Detection Kit; BD Pharmingen, San Jose, CA, USA). ER-positive MCF-7 and BT-474, as well as ER-negative SKBR-3 and MDA-MB231 cells (10 5 ), were treated with either DMSO or capsaicin (2 Â 10 À4 M) for 24, 48 and 72 h followed by Annexin V-FITC and PI labeling, which was performed according to the manufacturer's instructions.
Western blotting
Proteins from BT-474, SKBR-3 and MDA-MB231 cells harvested for western blotting were extracted with radioimmunoprecipitation assay buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 7.5) containing protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN, USA). Protein lysates (40 mg) were boiled in Laemmli sample buffer (Bio-Rad Laboratories, Hercules, CA, USA), resolved by electrophoresis on 4-15% SDS-polyacrylamide gels and transferred to polyvinylidene difluoride membranes. Membranes were probed with antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and developed using the enhanced chemiluminescence kit (Pierce, Rockford, IL, USA) whereas glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control.
Real-Time RT-PCR
Total cellular RNAs were isolated from BT-474, SKBR-3 and MDA-MB231 cells (10 7 ) using Trizol reagent (Life Technologies) and cDNAs were synthesized using Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's recommendation. Expression levels were determined using HotMaster Taq DNA Polymerase (Eppendorf, Westbury, NY, USA) and SYBRGreen I (Molecular Probes, Eugene, OR, USA) with the following primer sets: mRNA EGFR forward: 5 0 -TGCGTCTCTTGCCGG AAT-3 0 , mRNA EGFR reverse: 5 0 -GGCTCACCCTCCAGAA GCTT-3 0 ; mRNA HER-2 forward: 5 0 -TCTGGACGTGCC AGTGTGAA-3 0 , mRNA HER-2 reverse: 5 0 -TGCTCCCTGA GGACACATCA-3 0 ; 18S rRNA forward: 5 0 -AAACGGCTA CCACATCCAAG-3 0 , 18S rRNA reverse: 5 0 -CCTCCAATGG ATCCTCGTTA-3 0 . Reactions were carried out in triplicates using the iCycler iQ system (Bio-Rad Laboratories), and EGFR and HER-2 mRNA amplification was normalized against 18S rRNA as an internal control.
Boyden chamber assay for measurement of cell migration Boyden chemotaxis chambers (Nunc, Rochester, NY, USA) with 8 mm pore size were coated on the underside of the membrane with 50 mg/ml collagen for 1 h at room temperature. BT-474, SKBR-3 and MDA-MB231 cells were cultured overnight in serum-free media, detached from the culture dish by incubation with PBS containing 50 mM EDTA and resuspended in serum-free media with 0.5% bovine serum albumin (BSA). A total of 2 Â 10 5 cells in 300 ml serum-free media were added to the top of each chamber together with either diluent control (DMSO) or capsaicin (10 À6 or 10 À5 M); the lower chamber contained 300 ml of serum-free medium, 0.5% BSA and EGF (200 ng/ml). Chambers were placed in 24-well plates, and cells were allowed to migrate to the underside of the top chamber for 12 h. The migratory cells, which attached to the bottom surface of the membrane, were stained with 0.25% crystal violet in 50% methanol for 15 min. The stained cells were extracted with 10% acetic acid. The number of migratory cells per membrane was determined using a spectrophotometer (UNICO 1100 RS; UNICO, Dayton, NJ, USA) with an operating wavelength at 550 nm.
In vivo orthotopic tumor growth The in vivo behavior of breast cancer cells was investigated in triple deficient beige/nude/xid mice (BNX). Animal experiments were performed in accordance with the guidelines of Cedars-Sinai Research Institute and the National Institutes of Health. BNX nu/nu female mice (5-week old; Harlan SpragueDawley Inc., Indianapolis, IN, USA) were maintained in pathogen-free conditions and fed irradiated chow. MDA-MB231 cells (5 Â 10 6 ) in 0.1 ml of Matrigel (Collaborative Biological Products, Bedford, MA, USA) were injected into the mammary fat pad of each mouse (two injection sides per mouse), and capsaicin (5 mg/kg per day in 100 ml of PBS containing 0.3% ethanol) was started the next day and continued for 4 weeks. Control mice received vehicle (100 ml PBS per day containing 0.3% ethanol). Six mice were in each treatment group, and both groups received the agent by oral gavage 3 days per week. At killing, tumors were harvested from mice, and a portion of each tumor was snap-frozen in liquid nitrogen and stored at À80 1C until analysis. Tumor tissue homogenates were prepared in SDS lysis buffer of 50 mM Tris-HCl (pH 7.4), 2% SDS and protease inhibitor mixture as described previously (Solit et al., 2002) .
Induction of pre-neoplastic lesions in mammary glands and their prevention by capsaicin
The procedure was performed as described previously (Mehta et al., 2001) . Briefly, virgin BALB/c female mice, 3-4 weeks of age (Charles River Laboratories, Wilmington, MA, USA) were pretreated for 9 days with 17b-estradiol and progesterone. Thoracic mammary glands were removed, placed on silk rafts and incubated for 10 days in serum-free Waymouth MB752 medium (Life Technologies) containing the following growth-promoting hormones: insulin (5 mg/ml), prolactin (5 mg/ml), aldosterone (1 mg/ml) and hydrocortisone (1 mg/ml). The carcinogen DMBA at a dose of 2 mg/ml in diluent (DMSO) was added to the medium on day 3 for a duration of 24 h to induce mammary lesions. The DMBA-containing medium was removed, and the mammary glands were incubated for an additional 14 days with medium containing only insulin. Capsaicin (10 À8 -10 À5 M) or diluent control was included in the medium during the first 10 days of the in vitro culture to assess the ability of capsaicin to lower the incidence of the formation of mammary lesions. At the end of the culture period, the glands were fixed in formalin, stained in alum carmine solution (CAS no.: 1390-65-4) and evaluated for either presence or absence of mammary alveolar lesions. For mammary ductal lesions, aldosterone and hydrocortisone were replaced by 17b-estradiol (0.01 mg/ml) and progesterone (1 mg/ml) during the growth-promoting phase of the culture. This treatment selectively induces mammary ductal lesions (Mehta et al., 2000) . Mammary glands with ductal lesions were stained with hematoxylin and eosin. Finally, alveolar and ductal lesions were quantitatively determined by histopathological evaluations. All hormones and chemicals were purchased from Sigma Chemical Co.
Statistical analysis
For in vitro and in vivo studies, we evaluated the statistical significance of differences between two groups by two-sided Student's t-test. Asterisks shown in figures indicate significant differences of experimental groups in comparison with the corresponding control condition (*Po0.05, **Po0.01). P-values less than 0.05 were considered to be statistically significant. Data points in figures represent the means ± s.d. (standard deviation). in vitro assessments were performed in three independent experiments to confirm the results.
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